NSCLC [2016]: Bulletin #3
Gain new KOL insights on the latest events happening in non-small cell lung cancer (NSCLC), including: the EU approval of Novartis’s Mekinist (trametinib) in combination with Tafinlar (dabrafenib) for the treatment of BRAF V600-positive advanced NSCLC; Takeda's Alunbrig (brigatinib) being granted accelerated approval in the US for the treatment of patients with metastatic ALK-positive NSCLC who have progressed on or are intolerant to Xalkori (crizotinib; Pfizer); the Phase III ALEX study demonstrating Roche’s Alecensa (alectinib) to be superior to Xalkori in terms of progression-free survival (PFS) in the first-line treatment of ALK-positive NSCLC; and AbbVie’s PARP inhibitor, veliparib, failing to meet its primary endpoint of overall survival (OS) in a Phase III trial in NSCLC.
Business Questions
Business Questions
- How do KOLs view the EU approval of Novartis’s Mekinist in combination with Tafinlar for the treatment of BRAF V600-positive advanced NSCLC?
- Where do KOLs see Mekinist plus Tafinlar fitting into the NSCLC treatment algorithm?
- What factors could curtail the use of Mekinist in combination with Tafinlar?
- How do KOLs view the US approval of Takeda's Alunbrig and data from the ALTA trial?
- Where will Alunbrig be best positioned in the NSCLC treatment algorithm?
- How do KOLs view the positive outcome from the ALEX trial of Roche’s Alecensa and what will determine its success in first-line therapy?
- To what extent will Alecensa be used in the first-line treatment of ALK-positive NSCLC?
- How is the second-line treatment of ALK-positive NSCLC likely to evolve in light of recent events?
- How do KOLs view the Phase III failure of AbbVie’s veliparib and the future of PARP inhibitors in NSCLC?
